Lactoferrin as a Non-Hormonal Option in Endometriosis

Apr 30, 2026

Lactoferrin Targets Inflammation and Oxidative Stress in Endometriosis.

Key Points

Highlights:

Lactoferrin targets multiple pathways relevant to endometriosis, including inflammation, oxidative stress, iron metabolism, and cellular proliferation.
Its non-hormonal mechanism distinguishes it from current therapies that suppress ovulation.

Importance:

Non-hormonal therapeutic strategies that address key pathogenic mechanisms without compromising reproductive function remain an unmet need in endometriosis.

What’s done here?

This is a narrative review evaluating the potential role of lactoferrin in endometriosis.
It integrates current knowledge on endometriosis pathophysiology with the biological properties of lactoferrin.
Also reviews preclinical studies, observational data, and evidence from related clinical contexts.
It further explores potential mechanisms through which lactoferrin may influence disease processes.

Key results:

Lactoferrin demonstrates anti-inflammatory, antioxidant, and iron-modulating effects relevant to endometriosis.
Preclinical data suggest inhibition of pathways such as PI3K/Akt/mTOR, implicated in lesion progression.
Differential effects on endometriotic versus normal endometrial cells have been observed in experimental models.
Elevated lactoferrin-related markers have been reported in advanced disease, suggesting a potential biological role.
Clinical evidence specific to endometriosis remains limited, with most data derived from experimental or indirect settings.

Strengths and Limitations:

Strengths are: integrative overview linking lactoferrin biology to endometriosis pathophysiology; focus on a non-hormonal, multi-target approach; inclusion of mechanistic and translational perspectives.
Limitations are: predominantly preclinical and indirect evidence; lack of robust clinical trials in endometriosis; heterogeneity of available data; unresolved issues related to bioavailability and optimal delivery.

From the Editor-in-Chief – EndoNews

"This review revisits an increasingly relevant question in endometriosis management: whether non-hormonal strategies can meaningfully address a disease driven by multiple, interacting biological pathways.

By focusing on lactoferrin, the authors highlight a molecule with pleiotropic properties—anti-inflammatory, antioxidant, iron-modulating, and antiproliferative—that align conceptually with key features of endometriosis pathophysiology. This multi-target profile stands in contrast to current therapies, which predominantly act through hormonal suppression and are therefore inherently limited by effects on ovulation and long-term tolerability.

The appeal of lactoferrin lies in this breadth of biological activity. Chronic inflammation, oxidative stress, and dysregulated cellular proliferation are central components of endometriosis, and the ability to modulate several of these processes simultaneously is an attractive therapeutic concept. However, the transition from biological plausibility to clinical relevance remains incomplete.

Most of the evidence presented is derived from preclinical models, indirect clinical observations, or studies conducted in related conditions. Direct evidence demonstrating efficacy in endometriosis is limited, and the available data do not yet define the magnitude, consistency, or durability of any potential therapeutic effect. In this context, lactoferrin should be viewed as a candidate supported by mechanistic rationale rather than as an established treatment option.

Additional challenges remain. The pharmacokinetics of lactoferrin, particularly its limited oral bioavailability and short systemic half-life, raise practical questions regarding optimal dosing and delivery. Moreover, the heterogeneity of endometriosis itself—across phenotypes, disease stages, and symptom profiles—suggests that any therapeutic approach will require careful contextualization rather than broad generalization.

From a clinical perspective, the value of this work lies in reframing the therapeutic landscape. It underscores the need to move beyond single-pathway interventions toward approaches that reflect the complexity of the disease. At the same time, it reinforces the importance of maintaining a clear distinction between mechanistic promise and clinical evidence.

Lactoferrin represents a biologically coherent, non-hormonal concept that merits further investigation. Whether it can be translated into a clinically meaningful therapy will depend on well-designed studies that define its efficacy, safety, and place within the broader management of endometriosis."

Lay Summary

Current treatments for endometriosis largely rely on hormonal suppression, which can limit fertility and is often associated with recurrence after discontinuation.

A review published in Reproductive Sciences by Nakamura, Tanaka, and colleagues (Shiga University of Medical Science, Japan) explores the potential role of lactoferrin, a natural iron-binding glycoprotein, as a non-hormonal approach to endometriosis.

Lactoferrin is known for its anti-inflammatory, antioxidant, and antimicrobial properties. These features are particularly relevant in endometriosis, where chronic inflammation, oxidative stress, and abnormal cellular proliferation contribute to disease progression.

Experimental data suggest that lactoferrin may influence key signaling pathways involved in endometriosis, including those regulating cell growth and inflammation. In laboratory settings, it has been shown to inhibit proliferation of endometriotic cells while preserving normal endometrial cell function.

In addition, observational studies indicate that lactoferrin-related markers may vary with disease severity, suggesting a possible biological role in endometriosis. However, these findings remain inconsistent and are derived from limited datasets.

Importantly, most of the available evidence comes from preclinical and indirect clinical studies rather than trials specifically designed for endometriosis. While lactoferrin has an established safety profile in other contexts, its therapeutic role in endometriosis remains to be clearly defined.

These findings position lactoferrin as a biologically plausible, non-hormonal candidate that may complement existing treatment strategies, but further well-designed clinical studies are required before its clinical use can be established.